Optimi Health Corp. (OPTH) — Optimi Health shipped its first batch of naturally derived psilocybin, comprising biomass and finished 5mg capsules, from its Princeton, British Columbia facility to the United Kingdom to supply a planned Phase 2 clinical trial.
The export moved under Health Canada export and UK Home Office import authorizations, and the capsules use the same formulation already prescribed in Australia. The shipment demonstrates Optimi's cross-border regulated supply capability, with the trial partner and indication to be disclosed later.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.